Circumstances where stopping may be appropriate include intolerable side effects (such as persistent nausea or gastrointestinal symptoms), pregnancy or planning pregnancy, development of contraindications, or achievement of diabetes remission through significant lifestyle changes
Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice
Side effects are similar regardless of age: primarily gastrointestinal (nausea, constipation, diarrhea)
This shift occurred because GLP-1 drugs suppress users cravings for sweet and salty foods while increasing desire for healthy nutritious foods and savory umami proteins
Psarra, A., Nikolaou, A., Kokotou, M
Burton GJ, Hempstock J, Jauniaux E: Oxygen, early embryonic metabolism and free radical-mediated embryopathies